Gulf International Bank UK Ltd Sells 525 Shares of Catalent, Inc. (NYSE:CTLT)

Gulf International Bank UK Ltd reduced its stake in Catalent, Inc. (NYSE:CTLT) by 3.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 14,443 shares of the company’s stock after selling 525 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Catalent were worth $874,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent in the second quarter valued at $42,000. Longfellow Investment Management Co. LLC boosted its stake in shares of Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares during the last quarter. Intact Investment Management Inc. bought a new stake in Catalent during the third quarter worth about $73,000. Finally, Livforsakringsbolaget Skandia Omsesidigt increased its holdings in shares of Catalent by 1,400.0% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,500 shares of the company’s stock worth $91,000 after buying an additional 1,400 shares in the last quarter.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CTLT. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research note on Wednesday. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird restated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $59.83.

Catalent Price Performance

CTLT opened at $59.47 on Friday. The company has a fifty day moving average price of $59.98 and a two-hundred day moving average price of $58.07. The firm has a market capitalization of $10.79 billion, a PE ratio of -10.83, a P/E/G ratio of 2.06 and a beta of 1.16. Catalent, Inc. has a 52 week low of $32.38 and a 52 week high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the firm earned ($0.10) earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. As a group, analysts anticipate that Catalent, Inc. will post 0.95 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.